Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Zelira Therapeutics Ltd
G1GCurrent price
0.4 EUR
0 EUR (0.00%)
Last closed
0.7 AUD
Company
www.zeliratx.com
ISIN
AU000000ZLD1
Sector
Healthcare
Industry
Biotechnology
Exchange
Stuttgart Exchange
Capitalization
10 009 645 AUD
Yield for 12 month
-28.57 %
1Y
3Y
5Y
10Y
15Y
G1G
Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of a variety of medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter products, including SprinJene, an oral care product; and acne treatment products under the RAF FIVE name, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. In addition, it offers products for autism and chronic noncancer pain. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia. Address: 101 St Georges Terrace, Perth, WA, Australia, 6000
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
17.84 AUDP/E ratio
–Dividend Yield
–Current Year
+95 181 AUD
Last Year
+301 849 AUD
Current Quarter
+40 326 AUD
Last Quarter
+54 855 AUD
Current Year
+10 309 AUD
Last Year
-3 223 846 AUD
Current Quarter
-283 765 AUD
Last Quarter
-1 107 701 AUD
Key Figures G1G
1 year
3 years
5 years
10 years
EBITDA
-5 557 084 AUD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-18.87 %
PEG Ratio
–
Return On Equity TTM
-266.82 %
Wall Street Target Price
17.84 AUD
Revenue TTM
95 182 AUD
Book Value
-0.4 AUD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-82.1 %
Dividend Yield
–
Gross Profit TTM
-328 748 AUD
Earnings per share
-3.23 AUD
Diluted Eps TTM
-3.23 AUD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics G1G
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History G1G
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:175
Payout Ratio
–
Last Split Date
14.04.2022
Dividend Date
–
Stock Valuation G1G
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
155.6693
Price Sales TTM
103.8964
Enterprise Value EBITDA
-1.0946
Price Book MRQ
0.3247
Financials G1G
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators G1G
For 52 weeks
0.28 AUD
1.1 AUD
50 Day MA
0.75 AUD
Shares Short Prior Month
–
200 Day MA
0.69 AUD
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart